Devices/Safety Alert·FDA MedWatch Safety Alerts

Early Alert: Positive Pressure Breathing Device Issue from Baxter

HighPublished Jun 11, 2026· AI-analyzed Jun 11, 2026View original FDA source
AI-generated regulatory interpretation. The four sections below are an analyst-style summary produced by an AI model from the original FDA source. Always verify against the source before any regulatory, clinical, or commercial decision.
What happened

Baxter has issued an alert regarding Volara system patient circuits that may experience air and medication leaks from the nebulizer cup. These leaks can result in reduced oxygenation and ineffective delivery of nebulized medication during therapy.

Who it affects

Baxter, healthcare providers utilizing the Volara system, respiratory therapists, and hospital risk management departments.

Why it matters

The reported malfunction directly compromises the efficacy of respiratory therapy and patient oxygenation levels. This may necessitate a Class I recall if the FDA determines the malfunction poses a significant risk of serious adverse health consequences. Regulatory teams should anticipate heightened scrutiny regarding the manufacturing and quality control of these specific patient circuits.

Practical takeaway

Clinical engineering and QA teams should immediately identify and sequester affected Volara system patient circuits. Compliance departments should monitor for formal recall classification and ensure all field safety notices are documented within the firm's CAPA system.

FDA source material

Volara system patient circuits may leak air and medication from the nebulizer cup during therapy, leading to reduced oxygenation and ineffective nebulization.

Open in openFDA / FDA.gov
AI-generated interpretation. Always verify critical decisions against the original FDA source. Generated with google/gemini-3-flash-preview.